Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 19, 2026 11:40 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss

US FDA has approved Wegovy® HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight reduction long-term.
March 17, 2026 09:00 ET | Source: Portnoy Law

Novo Nordisk A/S Investigated by the Portnoy Law Firm

LOS ANGELES, March 17, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Novo Nordisk A/S (“Novo Nordisk" or the "Company") (NYSE:NVO) investors that the firm has initiated an investigation into...
March 17, 2026 05:28 ET | Source: Digbi Health

Digbi Health Capitalizes on GLP-1 Market Shift, Expands GLP Compass™, and Introduces Employer-Subsidized and Cash-Pay Pathways via Digbi RxFund™

This industry-first financial innovation bypasses PBM spread pricing, ensures ERISA compliance, gives employers total control over the Budget, Behavior, an
February 25, 2026 09:56 ET | Source: Schall Law

NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm

NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
February 09, 2026 07:28 ET | Source: Arch Biopartners

Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease

TORONTO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced that a scientific team led by Dr. Justin Chun at the...
February 05, 2026 19:53 ET | Source: PharmaZee

PharmaZee GLP-1 Prescription Information Updated as Novo Nordisk Raises Compounding Concerns and Consumer Interest in Telehealth Semaglutide Access Grows in 2026

PharmaZee telehealth platform information updated. Examining compounded vs FDA-approved GLP-1s amid Novo Nordisk compounding statement Feb 2026.
January 16, 2026 08:15 ET | Source: Arch Biopartners

Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board

TORONTO, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today the appointment of Dr. Patrick Vink as Chairman of the...
January 05, 2026 08:05 ET | Source: WW International Inc.

Weight Watchers Expands Its Integrated GLP-1 Platform with Access to Wegovy® Pill Advancing a New Standard for Long-Term Weight Health

NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight health, today announced access to Novo Nordisk’s newly...
November 13, 2025 19:37 ET | Source: Mangoceuticals, Inc.

Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs

Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) is issuing the following clarification regarding its press release issued...
November 13, 2025 07:00 ET | Source: Mangoceuticals, Inc.

Mangoceuticals Partners with Eli Lilly and Novo Nordisk to Deliver Affordable Access to Zepbound and Wegovy for Obesity Management

Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of health...